KIAA1751 Inhibitors
The chemical class known as KIAA1751 Inhibitors encompasses a variety of compounds targeting key signaling pathways and kinases associated with the KIAA1751 protein. These inhibitors act through direct mechanisms, blocking specific proteins or signaling components involved in pathways where KIAA1751 plays a role. For instance, Sorafenib, GDC-0879, Trametinib, and SCH772984 target the MAPK/ERK pathway by inhibiting RAF, MEK, and ERK, respectively. By disrupting this pathway, these inhibitors indirectly suppress KIAA1751, whose functions may be intertwined with MAPK/ERK signaling.
Y-27632 and SU6656 act as indirect inhibitors by targeting ROCK and Src family kinases, respectively. These kinases influence cellular processes associated with KIAA1751, and inhibiting them can modulate the protein's activity. Additionally, BMS-777607, LY294002, Rapamycin, SP600125, and PD98059 target c-MET, PI3K, mTOR, JNK, and MEK, respectively, affecting pathways connected to KIAA1751. Collectively, these inhibitors provide a valuable toolkit for studying the regulatory mechanisms and functional roles of KIAA1751 in cellular processes. The class's diversity allows researchers to explore different aspects of KIAA1751 biology, contributing to a comprehensive understanding of its involvement in cellular signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GDC-0879 | 905281-76-7 | sc-364497 | 5 mg | $225.00 | ||
GDC-0879 is a RAF inhibitor that disrupts the MAPK/ERK pathway. Inhibiting RAF can indirectly impact KIAA1751, as its functions may be intertwined with this signaling cascade. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK, a key component of the MAPK/ERK pathway. By blocking this pathway, it can indirectly suppress KIAA1751, as the protein's activities may be modulated by MEK-dependent signaling events. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH772984 inhibits ERK, a downstream effector in the MAPK/ERK pathway. Blocking ERK can indirectly inhibit KIAA1751 by disrupting signaling cascades crucial for the protein's activation and functions. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits Rho-associated protein kinase (ROCK). Inhibiting ROCK can influence cytoskeletal dynamics and cellular processes associated with KIAA1751, indirectly impacting the protein's activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 activates TGF-β receptors, modulating the TGF-β signaling pathway. By influencing this pathway, it can indirectly affect KIAA1751, as the protein may participate in processes regulated by TGF-β. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 inhibits Src family kinases, disrupting downstream signaling events. As KIAA1751 may be influenced by Src family kinases, inhibiting them can indirectly impact the protein's activity and related cellular processes. | ||||||
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | $400.00 $1269.00 | 1 | |
BMS-777607 inhibits c-MET, a receptor tyrosine kinase. By disrupting c-MET signaling, it can indirectly inhibit KIAA1751, as the protein may be involved in cellular processes influenced by c-MET activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, influencing the mTOR signaling pathway. By disrupting mTOR signaling, it can indirectly impact KIAA1751, as the protein may be involved in processes regulated by mTOR-dependent pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a component of the MAPK pathway. By blocking JNK activity, it can indirectly inhibit KIAA1751, as the protein's functions may be connected to the MAPK pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, a kinase in the MAPK pathway. By disrupting this pathway, it can indirectly suppress KIAA1751, as the protein's activities may be modulated by MEK-dependent signaling events. | ||||||